Lv2
150 积分 2024-01-10 加入
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
3个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
3个月前
已完结
Unravelling the GIPR agonist versus antagonist paradox
5个月前
已完结
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axis
5个月前
已完结
RIPK1 and necroptosis role in premature ageing
5个月前
已完结
From RIPK1 to Necroptosis: Pathogenic Mechanisms in Neurodegenerative Diseases
5个月前
已完结
RIPK1: A Promising Target for Intervention Neuroinflammation
5个月前
已完结
A novel gut-restricted RIPK1 inhibitor, SZ-15, ameliorates DSS-induced ulcerative colitis
6个月前
已完结
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)
6个月前
已完结
皖公网安备34019202002308
